| Authors: |
Johansson L; Biopharma Safety, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.; Department of Immunotechnology, Lund University, Lund, Sweden., Raggi G; AlveoliX AG, Swiss Organs-on-Chip Innovation, Bern, Switzerland., Cartwright J; Pathology, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Cambridge, UK., Lindqvist J; Integrated Bioanalysis, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Froment L; AlveoliX AG, Swiss Organs-on-Chip Innovation, Bern, Switzerland., Andersson P; Safety Innovation, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Betts C; Immune Safety, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Hornberg JJ; Safety Sciences, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Hobi N; AlveoliX AG, Swiss Organs-on-Chip Innovation, Bern, Switzerland., Ollerstam A; Biopharma Safety, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Fitzpatrick P; Biopharma Safety, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden. paul.fitzpatrick2@astrazeneca.com. |